Silexion Therapeutics Corp. Form 8-K Summary
Business context and reporting period
Filed September 25, 2026, under Item 3.01. The filing reports a Nasdaq continued-listing deficiency related to the bid price of Silexion’s ordinary shares. The company is an emerging growth company headquartered in Ramat-Gan, Israel, and its ordinary shares trade under “SLXN”; its warrants trade under “SLXNW.”
Financial metrics
This 8-K does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial performance metrics. The filing text does not provide a clear value for any such measures.
Material changes and listing status
- Nasdaq notified the company that its ordinary shares had a closing bid price below the $1.00 minimum required by Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days preceding September 25, 2026.
- The Nasdaq hearings panel will consider the bid price deficiency when deciding whether the company may remain listed on the Nasdaq Capital Market.
- The notification has no immediate effect. Ordinary shares will continue trading under “SLXN,” and the listed warrants will continue trading under “SLXNW.”
Outlook, risks, and contingencies
The company states that future compliance with the bid price requirement and other Nasdaq listing rules is uncertain. Failure to regain or maintain compliance could result in delisting. The filing provides no remediation plan, compliance deadline, hearing date, reverse-split proposal, or stated minimum bid-price recovery strategy.
Forward-looking statements are subject to risks and uncertainties, including the possibility that the company will not maintain Nasdaq compliance. Investors are directed to the risk factors in the company’s Form 10-K for the year ended December 31, 2025, filed March 17, 2026.
Key facts for investors to verify
- Nasdaq’s hearing panel decision and any applicable compliance or appeal deadlines.
- Whether the company’s bid price returns to at least $1.00 for the period required by Nasdaq.
- Any subsequent corporate action, including a reverse stock split or other measure intended to address the deficiency.
- Whether the ordinary shares and warrants continue trading on Nasdaq and whether additional listing deficiencies arise.
- The company’s latest financial condition and liquidity, which are not disclosed in this filing.